AstraZeneca and SOPHiA Genetics will team up in integrating the former's cancer drug development portfolio with the latter's multimodal approach that utilizes machine learning and artificial intelligence algorithms and the SOPHiA DDM platform. "Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response to therapy at the individual patient level," said Greg Rossi, AstraZeneca's Senior Vice President for Oncology Europe and Canada.